A Phase 1/2, Open Label, Single Infusion Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases (SB-728-T) in HIV Infected Subjects

Trial Profile

A Phase 1/2, Open Label, Single Infusion Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases (SB-728-T) in HIV Infected Subjects

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs SB 728 T (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Sponsors Sangamo BioSciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Feb 2014 According to ClinicalTrials.gov record; status changed from active, no longer recruiting to completed.
    • 18 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top